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Etanercept in Alzheimer disease
A randomized, placebo-controlled, double-blind, phase 2 trial
ABSTRACT
Objectives: To determine whether the tumor necrosis factor a inhibitor etanercept is well tolerated
and obtain preliminary data on its safety in Alzheimer disease dementia.
Methods: In a double-blind study, patients with mild to moderate Alzheimer disease dementia
were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over
a 24-week period. Tolerability and safety of this medication was recorded including secondary
outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12
weeks, 24 weeks, and following a 4-week washout period. This trial is registered with EudraCT
(2009-013400-31) and ClinicalTrials.gov (NCT01068353).
Results: Forty-one participants (mean age 72.4 years; 61%men) were randomized to etanercept
(n 5 20) or placebo (n 5 21). Etanercept was well tolerated; 90% of participants (18/20) com-
pleted the study compared with 71% (15/21) in the placebo group. Although infections were
more common in the etanercept group, there were no serious adverse events or new safety
concerns. While there were some interesting trends that favored etanercept, there were no sta-
tistically significant changes in cognition, behavior, or global function.
Conclusions: This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in
this small group of patients with Alzheimer disease dementia, but a larger more heterogeneous
group needs to be tested before recommending its use for broader groups of patients.
Classification of evidence: This study shows Class I evidence that weekly subcutaneous etaner-
cept is well tolerated in Alzheimer disease dementia. Neurology® 2015;84:2161–2168
GLOSSARY
AD5 Alzheimer disease; ADAS-cog5 Alzheimer’s Disease Assessment Scale–cognitive; BADLS5 Bristol Activities of Daily
Living Scale; CGI-I 5 Clinical Global Impression–Improvement; CI 5 confidence interval; CRP 5 C-reactive protein; IL 5
interleukin; IQR 5 interquartile range; ITT-LOCF 5 intention to treat–last observation carried forward; NPI 5 Neuropsychi-
atric Inventory; RPCT 5 randomized placebo-controlled trial; sMMSE 5 standardized Mini-Mental State Examination; TNF-
a 5 tumor necrosis factor a.
Acute and chronic systemic inflammation is characterized by the production of proinflammatory
cytokines including tumor necrosis factor a (TNF-a) from immune cells. TNF-a has a role in
systemic immune-to-brain communication by activating the central immune response.1 In
humans, low levels of chronic systemic inflammation are associated with evidence of microglial
activation.2 In animals, experimentally induced acute systemic inflammation results in an exag-
gerated central immune response leading to exacerbated neurodegeneration.3 In participants
with Alzheimer disease (AD) dementia, we have shown that modestly increased serum TNF-a
levels are associated with an increased rate of cognitive decline4 and an exaggeration of neuro-
psychiatric symptoms.5
Peer-reviewed published data on the use of the TNF-a inhibitor etanercept in AD dementia
is limited to small open-label studies6–8 purporting to deliver etanercept centrally9 through a
perispinal administration route. However, we have hypothesized that peripheral administration
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of a TNF-a inhibitor with high affinity and
specificity could, if well tolerated and safe,
have long-term beneficial cognitive and behav-
ioral efficacy in an AD dementia population
through inhibition of peripheral signaling to
the brain.10 Peripheral administration of TNF-
a inhibitors is licensed for a wide range of
rheumatologic and skin conditions in the
elderly but there are no randomized placebo-
controlled trials (RPCTs) of these drugs in AD
dementia that give comparative data regarding
tolerability, safety, or its effects (beneficial or
otherwise) on measures of clinical outcome.
We report the findings of a double-blind,
phase 2 RPCT examining the tolerability,
safety, and clinical effects on secondary clinical
psychometric measures of subcutaneous eta-
nercept in a mild to moderate AD population.
METHODS Standard protocol approvals, registrations,
and participant consents. The protocol and consent forms were
approved by a multicenter research ethics committee (Southamp-
ton and South West Hampshire REC [A], reference number
10/H0502). All participants provided informed consent before
screening procedures. The study was registered with EudraCT
(2009-013400-31) and ClinicalTrials.gov (NCT01068353).
Study design and participants. Safety and Tolerability of Eta-
nercept in Alzheimer’s Disease was an investigator-initiated, 24-
week, single-center, phase 2, double-blind RPCT to assess the
tolerability and safety of weekly 50 mg subcutaneous etanercept
in participants with AD dementia including cognitive, behavioral,
and functional outcomes.
The study was performed in accordance with the Declaration of
Helsinki and the principles of Good Clinical Practice. An indepen-
dent data and safety monitoring board monitored adverse events.
Figure 1 Trial profile
ITT-LOCF 5 intention to treat–last observation carried forward.
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At screening, eligible participants had to be aged 55 years or
older, be diagnosed with probable AD defined by the National
Institute of Neurological and Communicative Disorders and
Stroke–Alzheimer’s Disease and Related Disorders Association
criteria11 (diagnostic accuracy approximately 75%12,13), have a
modified Hachinski Ischemic Scale score14 of less than 5 points,
have a standardized Mini-Mental State Examination (sMMSE)15
score above 10 and below 27 points, have an informant spending
at least 24 hours per week with the participant, and be capable of
giving informed consent. Patients receiving a cholinesterase
inhibitor, memantine, or antidepressant medication were
required to have been on medication for a minimum period of
90 days before baseline. Patients with prior exposure to amyloid
vaccines, monoclonal antibodies, or IV immunoglobulins for the
treatment of AD were excluded. Patients with rheumatoid arthri-
tis, psoriasis, psoriatic arthritis, or ankylosing spondylitis, or those
taking anti–TNF-a agents, immunosuppressive drugs, and/or
oral prednisone.10 mg/d within the past 90 days were excluded.
Participants with known contraindications (active infections) or
cautions (previous significant exposure to tuberculosis, herpes
zoster, hepatitis B, heart failure [New York Heart Association
grades 3 and 4], demyelination disorders, and active malignancy
within past 5 years) to the use of etanercept were excluded.
Randomization and masking. ACE Pharmaceuticals BV
(Zeewolde, the Netherlands) manufactured the placebo and pack-
aged both the study medication and placebo to ensure blinding.
They used a computer to generate a simple random allocation
sequence (1:1), stratified in blocks of 4, to ensure 20 patients
in the treatment group (subcutaneous etanercept 50 mg) and
20 patients in the placebo group (water for injection). The inves-
tigators had no knowledge of the allocation sequence, which re-
mained concealed throughout the study. ACE Pharmaceuticals
loaded etanercept or placebo vials into serially numbered contain-
ers according to the allocation sequence. The loaded containers,
and the interventions inside them, were identical in appearance
and consistency to ensure concealment of the allocation sequence
from the investigators. After successful screening, participants
were assigned the container with the next available serial number
in strict chronological order. Study drug was administered by
weekly subcutaneous injection at home or in the clinic by study
team health professionals who were blinded to treatment
allocation.
Procedures. Following consent, patients underwent a screening
period including initial tuberculosis and infectious disease screen
(i.e., a chest radiograph, tuberculin skin, and an interferon
gamma release test). Participants fulfilling the inclusion and
exclusion criteria received etanercept 50 mg or placebo subcuta-
neously once per week for 24 weeks. This was followed by a 4-
week washout period in which no injections were given but in
which blinding was maintained. Clinic visits took place at
screening, baseline, week 12, week 24, and 4 weeks after the
last study drug injection (week 28). Patients who withdrew
from the study before scheduled clinic visits were seen within
1 week of withdrawal for an early termination visit. During
these visits, adverse event monitoring and psychometric
evaluation took place. Adverse events were recorded as
definitely related, probably related, possibly related, unlikely to
be related, or unrelated to the blinded study intervention.
Patients experiencing a serious adverse event or recurrent
infections were withdrawn from the study. Psychometric
measures included the sMMSE,15 Alzheimer’s Disease
Assessment Scale–cognitive section (ADAS-cog),16 Bristol
Activities of Daily Living Scale (BADLS),17 Clinical Global
Impression–Improvement (CGI-I) scale,18 Cornell Scale for
Depression in Dementia (Cornell),19 and the Neuropsychiatric
Inventory (NPI).20
At screening, blood samples were taken for routine clinical
laboratory assessments with additional measures of immunoglo-
bulins, anti-nuclear antibody, anti-cardiolipin, and a midstream
urine test for infection. Blood for DNA (principally for APOE
e4 analysis) was taken at baseline. APOE genotypes were deter-
mined by TaqMan genotyping of single nucleotide polymor-
phism (SNP) rs7412 and KASP genotyping of SNP rs429358.
Blood for routine laboratory assessments and serum inflammatory
markers were taken at baseline, week 12, week 24, and week 28
between 9 AM and 12 noon. Serum samples for inflammatory
markers were immediately placed on ice and stored within 2
hours at 280°C. Samples were analyzed blind to the treatment
allocation using a V-PLEX assay (Meso Scale Discovery [MSD]).
A protocol provided by MSD for custom assays was used with no
major modifications. Five serum inflammatory markers were
measured: TNF-a, interleukin (IL)-6, IL-10, IL-12p70, and C-
reactive protein (CRP).
Outcomes. The primary outcomes of the study were tolerability
and safety. Tolerability was measured by compliance (number of
injections given/number of planned injections) over the 24-week
trial period. Associated safety was measured by the number of
serious adverse events and adverse events during the study
treatment period coded using the Medical Dictionary for
Regulatory Activities (version 15.0) preferred term (http://www.
meddra.org). A symptom checklist was used at each visit to probe
for adverse events.
Secondary outcomes were differences in the change from
baseline of the psychometric measures (sMMSE, ADAS-cog,
BADLS, CGI-I, Cornell, and NPI) at 12 weeks and 24 weeks
between intervention groups for observed cases and intention
to treat–last observation carried forward (ITT-LOCF). In addi-
tion, emergent adverse events and psychometric changes follow-
ing a 4-week washout phase were measured.
Statistical analysis. This study was powered to assess tolerabil-
ity (dropout rates) of weekly etanercept 50-mg subcutaneous
injections and to identify adverse events associated with poor
tolerability in an AD dementia population. The study also
Table 1 Characteristics of patients entering the randomization phase
Characteristic
Etanercept 50 mg
(n 5 20)
Placebo
(n 5 21)
Mean difference (95%CI) or Χ2,
p value
Mean age, y (SE) 72.0 (2.1) 72.9 (2.2) 0.9 (25.3 to 7.1), p 5 0.8
Men, n (%) 15 (75) 10 (48) Χ2 3.2, p 5 0.07
White, non-Hispanic, % 1 (5) 0 (0) Χ2 1.1, p 5 0.3
Disease duration, y (SE) 5.1 (0.8) 4.1 (0.4) 21.0 (22.8 to 0.8), p 5 0.2
e4 carriers, n (%) 9 (45) 11 (52) Χ2 0.2, p 5 0.6
sMMSE pts (SE) 20.0 (1.4) 20.3 (1.2) 0.3 (23.3 to 4.0), p 5 0.9
ADAS-cog pts (SE) 25.8 (2.9) 25.7 (2.5) 20.1 (27.8 to 7.7), p 5 1.0
BADLS pts (SE) 16.5 (3.0) 14.0 (1.7) 22.5 (29.3 to 4.3), p 5 0.5
NPI pts (SE) 16.4 (2.5) 12.0 (2.7) 24.4 (211.8 to 3.0), p 5 0.2
Cornell pts (SE) 6.4 (0.8) 5.6 (1.0) 20.8 (23.4 to 1.9), p 5 0.6
Abbreviations: ADAS-cog 5 Alzheimer’s Disease Assessment Scale–cognitive; BADLS 5
Bristol Activities of Daily Living Scale; CI 5 confidence interval; Cornell 5 Cornell Scale
for Depression in Dementia; NPI 5 Neuropsychiatric Inventory; pts 5 points; SE 5 standard
error; sMMSE 5 standardized Mini-Mental State Examination.
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aimed to inform a potential phase 3 study of the variance and
mean differences in clinical outcome measures. To measure
dropout such that a 95% confidence interval (CI) about the
estimated rate had a margin of error of 615%, normal
approximation about a proportion showed that 36 to 41
participants would be required for a dropout rate
commensurate with previous AD studies of between 29% and
41%.21,22 This sample size also fell between 24 and 50
recommended as necessary to estimate SDs for a future phase 3
study.23–25 Efficacy analyses were performed on observed cases,
defined as all patients who received at least one dose of study
medication, and who provided data at baseline, week 12, and
week 24, and on ITT-LOCF cases, defined as all patients who
received at least one dose of study medication, and had at least
one postrandomization assessment. Study demographic
characteristics, efficacy measure outcomes, and serum
inflammatory proteins were assessed for normality using Q-Q
plots. Changes in psychometric measures and serum
inflammatory protein levels between the 2 intervention groups
were measured by unpaired t test and linear regression for
parametric variables or Mann–Whitney U test for
nonparametric variables. Clinical psychometric outcomes were
adjusted for baseline age, sex, and baseline psychometric score,
and were conducted at p , 0.0017 significance to allow for 30
multiple comparisons.
RESULTS Participant disposition. Participant disposi-
tion is detailed in figure 1. Between January 2011
and February 2013, a total of 67 patients were screened
at the Memory Assessment and Research Centre,
Southampton, UK, of whom 41 entered the study
and were assigned to either etanercept or placebo. Rea-
sons for screen failure included prior exposure to tuber-
culosis or latent tuberculosis (46% [12/26]),
monoclonal gammopathy of unknown significance
(12% [3/26]), MMSE screen failure (8% [2/26]),
abnormal chest radiology (8% [2/26]), skin cancer
(8% [2/26]), consent withdrawn before baseline (8%
[2/26]), abdominal aortic aneurysm requiring surgery
(4% [1/26]), clinically significant anemia (4% [1/26]),
and lack of adequate informant time (4% [1/26]).
Randomization phase. The mean age of the patients
entering the study was 72.4 (SD 9.7) years, and the
majority (61%) were men. Randomization of patients
at baseline led to 2 treatment groups that were similar
in demographic details, APOE e4 carrier status, and
psychometric test scores (p values in all cases .0.1
except sex, p 5 0.07) (table 1). There was no signif-
icant difference between treatment groups in the fre-
quency of participants taking a cholinesterase
inhibitor (16/20 [80%] etanercept vs 18/21 [86%]
placebo; Χ2 0.2, p 5 0.6), memantine (3/20 [15%]
etanercept vs 3/21 [14%] placebo; Χ2 0.004, p 5
0.9), or antidepressant medication (7/20 [35%] eta-
nercept vs 8/21 [38%] placebo; Χ2 0.01, p 5 0.8).
Tolerability and safety. Compliance to medication was
high over the 6-month trial period: overall median
100% (interquartile range [IQR] 87.5%–100%).
There was no significant difference in the median
compliance frequency between treatment groups
(etanercept 100% [IQR 95.8%–100%] vs placebo
94% [IQR 62.5%–100%]; MWU p 5 0.2). Eight
participants (20%) (2 on etanercept and 6 on
placebo) failed to complete the study following
randomization. Of the 8 noncompleters, 4
participants (all taking placebo) failed to complete the
study to 12 weeks, of whom one declined an early
termination visit, and 4 participants (2 taking placebo
and 2 taking etanercept) failed to complete the study to
24 weeks. Of the 2 noncompleters in the etanercept
group, one participant contracted a chest infection
and was withdrawn because of safety concerns and
one participant withdrew consent because of drug
Table 2 Incidence of adverse events by system organ class category
Disorder
Adverse events,
no. of events
(no. of participants)
Etanercept
(n 5 20)
Placebo
(n 5 21)
All disorders 42 events 55
events
Blood and lymphatic system (normocytic anemia, benign
monoclonal hypergammaglobulinemia)
0 (0) 3 (3)
Cardiac (abnormal heart sounds, angina pectoris, irregular heart
rate, atrial fibrillation)
2 (2) 2 (2)
Eye (eye pain) 0 (0) 2 (2)
Ear and labyrinth (wax impaction, deafness) 0 (0) 2 (1)
Gastrointestinal (nausea and vomiting, hematochezia, epigastric
discomfort, diarrhea, constipation, colonic polyp)
5 (5) 7 (5)
General fatigue 1 (1) 1 (1)
Injection-site reaction 4 (2) 1 (1)
Infections (gastroenteritis, respiratory tract, urinary tract,
pharyngitis, cellulitis)
11 (9) 7 (6)
Injury (falls) 2 (2) 4 (4)
Investigations (DNA antibody positive, increase serum CRP,
creatinine, transaminase, colonoscopy)
6 (6) 5 (5)
Metabolic (hyperkalemia, dehydration) 2 (1) 1 (1)
Musculoskeletal (sciatica, osteoarthritis, joint stiffness, back
pain, thoracic vertebral fracture, muscle weakness)
1 (1) 5 (3)
Neoplasms 0 (0) 0 (0)
Nervous system (parosmia, headache, parkinsonism, balance
disorder)
2 (2) 2 (2)
Psychiatric (poor sleep, confusional state, behavioral symptoms,
mood alteration, hallucinations, delusions)
3 (3) 6 (5)
Renal and urinary (urinary frequency, urinary incontinence) 1 (1) 1 (1)
Respiratory (yawning) 1 (1) 0 (1)
Skin (varicose eczema, hyperhidrosis, seborrheic dermatitis,
seborrheic keratitis, eczema)
1 (1) 4 (3)
Vascular (hypertension, lymphedema) 0 (0) 2 (2)
Abbreviation: CRP 5 C-reactive protein.
Adverse events include definitely, probably, possibly, unlikely, and not thought to be related
to the study intervention. Participants could report multiple events in any category. Adverse
drug reactions are coded by the MedDRA preferred term (Medical Dictionary for Regulatory
Activities, MedDRA 15.0).
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delivery logistic problems. Of the 6 noncompleters in
the placebo group, 5 participants were withdrawn
because of safety concerns (one participant contracted
a urinary tract infection, one developed a monoclonal
gammopathy of unknown significance, one experienced
blood in stools, one experienced worsening of behavioral
symptoms, and one participant required an elective hip
replacement). One participant withdrew consent
because of family commitments.
The overall study completion was 81% (33/41).
There was no statistical difference in the completion
rates between those allocated to etanercept and those
allocated to placebo (90% [18/20] from the etaner-
cept group were completers vs 71% [15/21] from
the placebo group; Fisher exact test, p 5 0.2).
A total of 97 adverse events occurred during the
24-week randomization phase of the study with one
serious adverse event (one participant in the placebo
arm was admitted to hospital with a urinary tract
infection). Adverse events grouped by system are
summarized in table 2. There were 42 (43%) adverse
events in 20 participants in the etanercept group and
55 (57%) in 21 participants in the placebo group.
Infections, injection site reactions, and investigational
abnormalities were present in a greater number of
participants in the etanercept arm compared with
the placebo arm but no statistical differences were
found between groups (Χ2, all p . 0.1).
Secondary clinical outcomes. Changes in psychometric
scores for observed cases and ITT-LOCF at 12 and
24 weeks after randomization are shown in table 3
and figure 2. One participant randomized to placebo
withdrew from the study at 4 weeks and declined an
early termination assessment of clinical outcomes.
Increases in psychometric scores from baseline
indicate a worsening in outcomes except for the
sMMSE for which an increase indicates an
improvement. None of the clinical outcomes were
statistically significant between treatment groups
following Bonferroni correction.
Washout phase. No serious adverse events occurred
during the 4-week washout phase of the study. Six
participants experienced a total of 7 adverse events:
3 adverse events (fall, upper respiratory tract
infection, gastric irritation) in 3 participants taking
etanercept previously and 4 adverse events
(disturbed sleep, fall, constipation and fall) in 3
participants taking placebo previously.
Allowing for Bonferroni correction, there were no
significant differences in the change of psychometric
scores for the sMMSE, ADAS-cog, BADLS, NPI, Cor-
nell, or CGI-I during the 4-week washout phase of the
study between those participants previously taking eta-
nercept compared with those previously taking pla-
cebo: sMMSE: etanercept 20.3 vs placebo 20.1
points (mean difference 20.2 points [95% CI 1.7 to
Table 3 Changes in psychometric scores 12 weeks and 24 weeks for observed and ITT-LOCF after randomization compared with baseline
Week 12 Week 24
Etanercept
(n 5 20) (SE)
Placebo
(n 5 17) (SE)
Mean difference
correcteda (95% CI) p Value
Etanercept
(n 5 18) (SE)
Placebo
(n 5 15) (SE)
Mean difference
correcteda (95% CI) p Value
Observed
cases
sMMSE 20.6 (0.5) 20.5 (0.7) 0.004 (21.9 to 1.9) 1.0 20.1 (0.5) 21.9 (1.2) 22.5 (25.2 to 0.2) 0.07
ADAS-cog 1.3 (1.4) 1.4 (1.5) 0.2 (24.3 to 4.6) 0.9 3.2 (1.8) 5.6 (2.0) 1.2 (25.1 to 7.5) 0.7
BADLS 21.1 (2.1) 1.2 (0.9) 0.6 (24.6 to 5.8) 0.8 0.8 (1.2) 6.0 (2.1) 5.6 (0.4 to 10.9) 0.04
NPI 22.0 (2.7) 3.8 (1.6) 4.4 (23.0 to 11.7) 0.2 20.3 (3.3) 10.2 (3.6) 13.2 (2.4 to 24.0) 0.02
Cornell 20.2 (0.9) 0.1 (1.0) 0.1 (22.8 to 3.0) 0.9 0.4 (1.0) 1.9 (1.5) 1.6 (22.3 to 5.5) 0.4
CGI-I 0.4 (0.2) 0.5 (0.2) 0.2 (20.5 to 0.8) 0.6 0.6 (0.2) 0.9 (0.3) 0.3 (20.6 to 1.1) 0.3
ITT-LOCF
sMMSE 20.6 (0.5) 20.5 (0.7) 0.05 (21.7 to 1.9) 0.9 20.2 (0.5) 21.4 (1.0) 21.4 (23.8 to 1.0) 0.2
ADAS-cog 1.3 (1.4) 1.9 (1.4) 0.6 (23.6 to 4.8) 0.8 2.9 (1.7) 5.1 (1.6) 1.6 (23.5 to 6.6) 0.5
BADLS 21.1 (2.1) 1.4 (0.9) 0.5 (24.2 to 5.2) 0.8 0.5 (1.2) 4.9 (1.7) 3.7 (20.9 to 9.3) 0.1
NPI 22.0 (2.7) 3.7 (1.5) 4.2 (22.6 to 11.1) 0.2 0.8 (3.1) 6.9 (3.2) 6.5 (23.4 to 16.5) 0.2
Cornell 20.2 (0.9) 0.4 (0.8) 0.2 (22.4 to 2.9) 0.9 0.5 (0.9) 1.9 (1.2) 0.8 (22.4 to 3.9) 0.6
CGI-I 0.4 (0.2) 0.5 (0.2) 0.1 (20.5 to 0.7) 0.7 0.7 (0.2) 0.7 (0.3) 0.1 (20.8 to 0.6) 0.8
Abbreviations: ADAS-cog 5 Alzheimer’s Disease Assessment Scale–cognitive; BADLS 5 Bristol Activities of Daily Living Scale; CGI-I 5 Clinical Global
Impression–Improvement; CI 5 confidence interval; Cornell 5 Cornell Scale for Depression in Dementia; ITT-LOCF 5 intention to treat–last observation
carried forward; NPI 5 Neuropsychiatric Inventory; SE 5 standard error; sMMSE 5 standardized Mini-Mental State Examination.
All p values are 2-sided.
aCorrected for baseline age, sex, and psychometric score.
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22.0]), p5 0.9; ADAS-cog: etanercept 1.3 vs placebo
24.2 points (mean difference 5.5 points [95% CI
9.0–2.0]), p 5 0.003; BADLS: etanercept 2.4 vs pla-
cebo 21.7 points (mean difference 4.1 points [95%
CI 7.0 to21.4]), p5 0.004; NPI: etanercept22.4 vs
placebo23.5 points (mean difference 1.1 points [95%
CI 7.7 to25.6]), p5 0.7; Cornell: etanercept20.8 vs
placebo22.1 points (mean difference 1.2 points [95%
CI 3.1 to 20.6]), p 5 0.6; CGI-I: etanercept 0 vs
placebo 0 points (mean difference 0 points [95% CI
0.7 to 20.8]), p 5 1.0.
Serum inflammatory markers. Serum was not available
in one (placebo randomized) participant. Serum levels
for TNF-a, IL-6, IL-10, IL-12p70, and CRP for all
other participants completing the study (18
randomized to etanercept and 14 to placebo) are
shown at baseline (week 0), week 12, week 24, and
after the 4-week washout phase (week 28) in table e-1
on the Neurology® Web site at Neurology.org. At
baseline, there were no statistical differences in
serum TNF-a or IL-12 between the treatment and
placebo groups. Following randomization, serum
TNF-a was higher in the treatment compared with
the placebo group at weeks 12 and 24 and was still
significantly increased, although diminished, at week
28. Serum IL-12 was also higher in the treatment
compared with the placebo group at week 12 but
not significantly different from placebo at week 24
Figure 2 Mean change in outcome scores (observed cases weeks 12 and 24) and ITT-LOCF (week 24) from baseline
ADAS-cog5 Alzheimer’s Disease Assessment Scale–cognitive; BADLS5 Bristol Activities of Daily Living Scale; CGI-I5Clinical Global Impression–Improve-
ment; Cornell 5 Cornell Scale for Depression in Dementia; ITT-LOCF 5 intention to treat–last observation carried forward; MMSE 5 standardized Mini-
Mental State Examination; NPI 5 Neuropsychiatric Inventory.
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or week 28. At baseline, serum IL-10 was statistically
lower in the treatment compared with the placebo
group. Following randomization, serum IL-10 was
no longer significantly different from placebo at
week 12 or 24, but following withdrawal was lower
in the treatment arm at week 28. There were no
significant differences between the serum
inflammatory markers IL-6 or CRP between the
treatment and placebo groups at baseline or weeks
12, 24, and 28.
DISCUSSION Of the 67 patients screened for this
study, 26 failed to meet the inclusion or exclusion cri-
teria. The 2-year recruitment period was the result of
screening failures, the majority of which (n 5 12
[46%]) were attributable to prior exposure to
tuberculosis, of high frequency in the United
Kingdom aged population,26 and to drug delivery
delay following Pfizer’s acquisition of Wyeth.
Compliance was high over the 24-week trial period
with no significant differences between treatment
groups. Ninety percent of patients (18/20)
completed the etanercept arm of the study. There
were no serious adverse events in the etanercept
arm. Adverse events, including infection rates and
injection-site reactions, were in keeping with the
known, and potentially serious, side effects of
etanercept,27 but no new safety concerns were
found regarding the use of etanercept in patients
with AD dementia.
Whereas the psychometric changes in the placebo
arm are in keeping with observed changes reported
elsewhere in similar populations,28,29 the change in
ADAS-cog was double than anticipated.4 While every
attempt was made to improve internal validity by
ensuring raters received the same psychometric rating
training and, wherever possible, not change between
visits, small numbers in the study cannot rule out the
random allocation of a more rapidly declining group
to the placebo arm and differences between groups
should be viewed with caution. There was no statis-
tical difference between the cognitive, functional, and
behavioral assessments in the etanercept compared
with the placebo group (or worsening following with-
drawal) after Bonferroni correction. Serum TNF-a
showed a marked increase in the etanercept-treated
group compared with the placebo group, reflecting
the increased half-life of the inert dimeric fusion pro-
tein after binding of TNF-a.30,31
The use of subcutaneous etanercept in this study is
based on the hypothesis of modifying long-term, low-
grade peripheral systemic inflammation,1,4,10,32 a
different concept than the hypothesized rapid modi-
fication of central TNF-a through a periventricular
approach,7 which has not been participant to an
RPCT and remains highly controversial.33
The current study should not be seen to support
the use of unlicensed subcutaneous etanercept for
the treatment of AD dementia. Etanercept has recog-
nized potentially serious adverse effects in the popula-
tion,27 and independent validation is needed in a
larger more heterogeneous AD dementia population
to fully assess the long-term safety and clinical effects
of this approach.
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